MapLight Therapeutics (NASDAQ: MPLT) debuted on NASDAQ in October 2025 and raised $296.3 million in IPO gross proceeds; Needham has initiated coverage. The company is focused on central nervous system disorders. The report is factual and provides no guidance, valuation, or operational updates.
MapLight Therapeutics (NASDAQ: MPLT) debuted on NASDAQ in October 2025 and raised $296.3 million in IPO gross proceeds; Needham has initiated coverage. The company is focused on central nervous system disorders. The report is factual and provides no guidance, valuation, or operational updates.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
